Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound having a structure according to

Formula I:

1

2

3

4

6

8

9

10

11

12

13

14

15

16

17

18

19

wherein

5 a is either 0 or 1;

b is either 0 or 1;

7 the dashed line represents a double bond between C* and N when a is 0;

 R^2 is a member selected from (=0) and NR^7R^8 , such that when R^2 is (=0), b is 0, and when R^2 is NR^7R^8 , b is 1;

 R^4 is a member selected from H, halogen, OR^3 , NR^7R^8 , halogen, nitrile, and substituted and unsubstituted (C_1 - C_5)alkyl;

R⁶ is a member selected from H, halogen, **OR**³ <u>substituted or unsubstituted O-alkyl</u>,

NR³R³, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl,
substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or
unsubstituted 5- to 7- membered heterocycloalkyl, substituted or unsubstituted
acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

R⁷, R⁸, R⁵ and R¹ are members independently selected from H, OR³, NR³R³, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted 5- to 7-

3

20	membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or
21	unsubstituted aryl, and substituted or unsubstituted heteroaryl;
22	R ³ is independently selected from H, substituted or unsubstituted alkyl and substituted or
23	unsubstituted acyl;
24	wherein R ⁷ and R ⁸ together with the nitrogen to which they are joined optionally form a
25	substituted or unsubstituted 5- to 7- membered ring;
26	wherein R ⁸ and R ⁵ together with the atoms to which they are joined optionally form a
27	substituted or unsubstituted 5- to 7- membered ring;
28	wherein R ⁵ and R ⁶ together with the atoms to which they are joined optionally form a
29	substituted or unsubstituted 5- to 7- membered ring; and
30	wherein at least one member selected from R ³ , R ⁵ , R ⁷ , and R ⁸ , alone or together with the
31	atom to which it is covalently bonded, is selected from carbamate and urea linkers.
1	2. (Original) The compound according to claim 1, wherein R ² is selected
2	from (=O), -NH ₂ , and -NHOH.

- 1 3. (Original) The compound according to claim 1, wherein R⁴ is selected from F, CN, -CCH, -CCMe, and CH₃.
- 1 4. (Original) The compound of claim 1, wherein R¹ comprises a hydroxyl 2 moiety.
- 1 5. (Original) The compound of claim 4, wherein R¹ comprises a saccharyl 2 moiety.
- 1 6. (Original) The compound of claim 1, wherein R¹ is a structure according 2 to Formula II:

$$R^{11}$$
 $C^{a---}C^{b}$
 R^{10}
 R^{9}
(II)

wherein

4

5

6

7

8

9

. 10

11

12

13

14

15

16

17

4

5

6

7

8

9

10

11

the dashed line represents a double bond between C^a and C^b;

R⁹, R¹⁰ and R¹¹ are members independently selected from H, -OH, -OR¹², -NH₂,


-NO₂, -SO₂NH₂, N₃, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7- membered cycloalkyl, substituted or unsubstituted or unsubstituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

wherein R¹² is selected from an amino acid and a peptide comprising between 2 and 5 amino acids;

wherein R⁹ and R¹⁰ together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7- membered ring;

wherein R¹⁰ and R¹¹ together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7- membered ring.

7. (Original) The compound according to claim 6, wherein R⁹, R¹⁰ and R¹¹
are members independently selected from H, OH, (R¹³)₃SiO-, and a structure according to
Formula III:



wherein each R¹³ is independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

wherein more than one R¹³ together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7- membered ring; and

1

3

4

5

6

7

8

9

1

2

3

1

2

- wherein R¹⁶, R¹⁷, and R¹⁸ are independently selected from substituted and unsubstituted alkyl.
 - 8. (Original) The compound of claim 7, wherein R¹⁶, R¹⁷, and R¹⁸ are ethyl.
- 9. (Original) The compound according to claim 1, wherein R³, R⁵, R⁷, and R⁸ are independently selected from H and a structure according to Formula IV:

$$R^{14}$$
 (IV)

wherein R¹⁴ is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, an amino acid, and a peptide comprising between 2 and 5 amino acids; wherein if R⁸ is a structure according to Formula IV, then R⁷ is H.

10. (Original) The compound according to claim 1, wherein R³, R⁵, R⁷, and R⁸ are independently selected from H and a structure according to Formula V:

$$\mathbb{R}^{15}$$
 (V)

wherein R¹⁵ is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted acyl, substituted or unsubstituted acyl, substituted or unsubstituted heteroaryl, an amino acid, and a peptide comprising between 2 and 5 amino acids;

wherein if R⁸ is a structure according to Formula V, then R⁷ is H.

11. (Original) The compound according to claim 9, wherein R^{14} is selected from substituted or unsubstituted (C₄-C₁₂)alkyl, benzyl, 2-nitro-furanyl, retinol, α -tocopherol,


- (Original) The compound according to claim 10, wherein R¹⁵ is selected **12**. 1
- from substituted or unsubstituted (C_4 - C_{12})alkyl, benzyl, 2-nitro-furanyl, retinol, α -tocopherol, 2

- (Original) The compound according to claim 11, wherein R¹⁴ is 13. 1
- 2 unsubstituted (C₆-C₁₀)alkyl.

4

3

- (Original) The compound according to claim 12, wherein R¹⁵ is 14. 1
- unsubstituted (C₆-C₁₀)alkyl. 2
- (Original) The compound according to claim 9, wherein R² is selected **15**. 1
- 2 from (=O), -NH₂, and -NHOH.
- (Original) The compound according to claim 10, wherein R² is selected 16. 1
- 2 from (=0), $-NH_2$, and -NHOH.



Appl. No. 10/816,161 Amdt. dated January 5, 2006 Reply to Office Action of September 20, 2005

(Cancelled) The method of claim 26, wherein said retrovirus is selected 1 **27**. from HIV and Hepatitis B. 2 (Cancelled) The method of claim 26, wherein said ribovirus is 28. 1 2 Hepatitis C. (Cancelled) A method for treating cancer comprising administering to a **29**. 1 subject in need of such treatment a therapeutically effective amount of a compound according to 2 3 claim 1. (Cancelled) The method of claim 29, wherein said cancer is a 1 **30**. 2 hematopoietic cancer. (Currently amended) A pharmaceutical composition comprising a **31**. 1 pharmaceutically acceptable carrier and a compound according to Formula I claim 1. 2